NEULANDLAB Stock Overview
Neuland Laboratories Limited produziert und verkauft aktive pharmazeutische Wirkstoffe (APIs) in Indien, Europa, den Vereinigten Staaten und international.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for NEULANDLAB from our risk checks.
Neuland Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹6,503.45 |
| 52 Week High | ₹7,318.30 |
| 52 Week Low | ₹1,950.00 |
| Beta | 1.03 |
| 1 Month Change | -7.17% |
| 3 Month Change | 16.69% |
| 1 Year Change | 215.81% |
| 3 Year Change | 166.84% |
| 5 Year Change | 841.03% |
| Change since IPO | 6,745.74% |
Recent News & Updates
Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17
Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Recent updates
Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Neuland Laboratories (NSE:NEULANDLAB) Has A Pretty Healthy Balance Sheet
Mar 15Can You Imagine How Elated Neuland Laboratories' (NSE:NEULANDLAB) Shareholders Feel About Its 391% Share Price Gain?
Feb 28Don't Ignore The Fact That This Insider Just Sold Some Shares In Neuland Laboratories Limited (NSE:NEULANDLAB)
Feb 12Neuland Laboratories Limited (NSE:NEULANDLAB) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 04Neuland Laboratories Limited's (NSE:NEULANDLAB) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Feb 03Read This Before Selling Neuland Laboratories Limited (NSE:NEULANDLAB) Shares
Jan 18
If You Like EPS Growth Then Check Out Neuland Laboratories (NSE:NEULANDLAB) Before It's Too Late
Jan 01Is Neuland Laboratories Limited (NSE:NEULANDLAB) Popular Amongst Insiders?
Dec 14Did Business Growth Power Neuland Laboratories' (NSE:NEULANDLAB) Share Price Gain of 117%?
Nov 26These 4 Measures Indicate That Neuland Laboratories (NSE:NEULANDLAB) Is Using Debt Reasonably Well
Nov 08Shareholder Returns
| NEULANDLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.9% | 1.9% | 3.6% |
| 1Y | 215.8% | 63.3% | 48.8% |
Rendite im Vergleich zur Industrie: NEULANDLAB übertraf die Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 65.4 erzielte.
Rendite vs. Markt: NEULANDLAB übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von 44.7 erzielte.
Price Volatility
| NEULANDLAB volatility | |
|---|---|
| NEULANDLAB Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.4% |
| 10% least volatile stocks in IN Market | 4.2% |
Stabiler Aktienkurs: NEULANDLAB hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.
Volatilität im Zeitverlauf: NEULANDLABDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,554 | Davuluri Rao | https://www.neulandlabs.com |
Neuland Laboratories Limited produziert und verkauft aktive pharmazeutische Wirkstoffe (APIs) in Indien, Europa, den Vereinigten Staaten und international. Die APIs des Unternehmens werden in verschiedenen therapeutischen Bereichen eingesetzt, darunter Antiasthmatika, Herz-Kreislauf-Medikamente, Antimykotika, Antikonvulsiva, Zentralnervensystem, Fluorchinolone, Antipsychotika, Antibiotika und Antiparkinsonmittel. Das Unternehmen bietet auch kundenspezifische Herstellungslösungen sowie Peptidsynthese-Dienstleistungen an.
Neuland Laboratories Limited Fundamentals Summary
| NEULANDLAB fundamental statistics | |
|---|---|
| Market cap | ₹83.38b |
| Earnings (TTM) | ₹3.17b |
| Revenue (TTM) | ₹15.81b |
26.3x
P/E Ratio5.3x
P/S RatioIs NEULANDLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEULANDLAB income statement (TTM) | |
|---|---|
| Revenue | ₹15.81b |
| Cost of Revenue | ₹7.62b |
| Gross Profit | ₹8.18b |
| Other Expenses | ₹5.01b |
| Earnings | ₹3.17b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 247.13 |
| Gross Margin | 51.77% |
| Net Profit Margin | 20.06% |
| Debt/Equity Ratio | 8.9% |
How did NEULANDLAB perform over the long term?
See historical performance and comparison